Overall, adjusted operating expenses increased $56 million, driven by costs related to Bioness and Misonix when compared to the prior year. In addition, the prior year benefited from a decrease in expenses of $25 million related to the change in fair market value of accrued equity-based compensation associated with our IPO closing price. Now turning to our bottom line financial metrics. Adjusted EBITDA totaled $7 million, compared to $11 million from the prior year.